About 

La vendita allo scoperto per Universe Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Universe Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Universe Pharmaceuticals (NASDAQ:UPC) Azioni, Report sulle vendite allo scoperto

Universe Pharmaceuticals

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals Inc

UNI-PRESIDENT C/H UNS/ADR by Uni-President China Holdings Ltd.

Uni-President China Holdings Ltd

UNIVERSAL POTASH CORP by Universal Potash Corp.

Universal Potash Corp

News

Guidance

BBSI

Barett Business Services Sees FY24 Gross Billings Growth 7%-8%.

AppLovin Sees Q4 2024 Revenue $1.24B-$1.26B; Sees Adj. EBITDA $740M-$760M

SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) reported quarterly losses of $(15.33) per share. This is a 2687.27 percent decrease over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $260.903 million which missed the analyst consensus estimate of $269.380 million by 3.15 percent. This is a 64.03 percent decrease over sales of $725.305 million the same period last year.

Earnings

Earnings Misses

SEDG

SolarEdge Technologies Q3 2024 Adj. EPS $(15.33) Down From $(0.55) YoY, Sales $260.903M Miss $269.380M Estimate

Regional bank stocks surged on Wednesday, marking their strongest one-day performance in four years as investors bet on a more favorable banking sector environment when Donald Trump returns <a href="https://www.benzinga.com/topic/donald-trump">to the White House.</a>
The SPDR S&amp;P Regional Banking ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>) — which tracks a basket of 147 small- and mid-cap U.S. banks — jumped 13.4%, posting its largest rally since November 2020. Back then, the announcement of the first COVID-19 vaccine sparked a broad market rebound.
In Wednesday's trading, regional banks outshined even the biggest U.S. banks. Financials were the top-performing sector in the S&amp;P 500, with the Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) rising 6%. 
Yet regional banks saw an even greater lift, driven by expectations that Trump&#8217;s policies will uniquely benefit smaller, domestic-focused institutions.
The strength in regional banks also fueled a broader rally in small-cap stocks. The Russell 2000 index, which includes a significant portion of regional banks, surged 6% as investor optimism spread across smaller, U.S.-centric companies.
Regional banks are the most representative sector of the Russell 2000 index, which soared by 6% on Wednesday. 
<h4 class="wp-block-heading">Chart: Regional Banks Mark Best Day Since Covid-19 Vaccine Announcement </h4>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65-1024x501.png" alt="" class="wp-image-633735" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160718/image-65.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">JPMorgan&#8217;s Elian Identifies 7 Tailwinds For Regional Banks</h3>
JPMorgan analyst Anthony Elian sees multiple factors that could fuel a strong performance for regional banks under Trump&#8217;s leadership.
&#8220;We view these results as being favorable for the regional bank sector tied to several tailwinds,&#8221; Elian wrote in a note on Wednesday. 
He highlighted seven main drivers:
<ol>
<li>Increased lending activity – A pro-business and onshoring agenda is expected to boost lending, potentially driving a revival in loan growth across the industry.</li>
<li>Lower corporate taxes – Trump&#8217;s anticipated tax cuts could enhance profitability for regional banks by reducing their tax burden.</li>
<li>Eased regulatory environment – According to Elian, &#8220;a second Trump administration would include an easier backdrop for regulation for the industry,&#8221; which could help banks reduce compliance costs and expand operations.</li>
<li>Uptick in M&amp;A activity – With a favorable regulatory climate, the sector could see an increase in mergers and acquisitions, a trend that was prevalent during Trump's first term and could benefit mid-sized banks seeking growth.</li>
<li>Attractive valuations – Elian noted that regional banks remain undervalued by historical standards, suggesting &#8220;there is still material upside on the table.&#8221;</li>
<li>Steep Treasury yield curve, Fed still in easing mode – With the Treasury yield curve in a steep pattern and the Federal Reserve to keep lowering rates, regional banks could benefit from improved net interest margins (NIMs) and net interest income (NII), boosting their earnings and profitability over time.</li>
<li>Underweight positioning – Elian highlighted that investors are still largely underweight on regional bank stocks, indicating room for increased demand as sentiment shifts.</li>
</ol>
JPMorgan&#8217;s Elian identified a few standout names in the regional banking space. Among his top picks are First Citizens BancShares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) and Western Alliance Bancorporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>), both of which are well-positioned to take advantage of the expected uptrend in the sector.
<h3 class="wp-block-heading">Trump&#8217;s 2016 Win Offers Historical Context For Sector Rally</h3>
The market's optimism is further bolstered by historical precedent. Regional bank stocks were among the biggest early beneficiaries following Trump's 2016 election victory.
Between Nov. 9, 2016, and Jan. 10, 2017, the KRE ETF surged nearly 20%, significantly outperforming other sectors during that period.
<h4 class="wp-block-heading">Chart: Performance Of Regional Bank ETF (Nov. 9, 2016 &#8211; Jan. 10, 2017) </h4>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64-1024x501.png" alt="" class="wp-image-633728" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64-768x376.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64-1536x752.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06160352/image-64.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41783357/how-did-s-p-500-sectors-perform-during-trumps-first-term-could-this-time-be-different">How Did S&amp;P 500 Sectors Perform During Trump&#8217;s First Term? Could This Time Be Different?</a></li>
</ul>
Image: Midjourney

Sector ETFs

Politics

Markets

Movers

FCNCA

Regional Bank Stocks Notch Strongest Day In 4 Years: Why Analysts Expect 'Several Tailwinds' From Trump Policies

2024 Financial Outlook
Certara is updating its 2024 outlook, and expects the following:
<ul>
<li>Full year 2024 revenue to be in the range of $380 million to $385 million.</li>
<li>Full year adjusted EBITDA to be in the range of $120 million to $124 million.</li>
<li>Full year adjusted diluted earnings per share is expected to be in the range of $0.41 - $0.44.</li>
<li>Fully diluted shares are expected to be in the range of 160 million to 162 million.</li>
</ul>

CERT

Certara Sees FY24 EPS $0.41-$0.44 Vs $0.41 Est.; Revenue $380M-$385M Vs $386.5M Est.

AMC Enter Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.11) by 63.64 percent. The company reported quarterly sales of $1.35 billion which beat the analyst consensus estimate of $1.33 billion by 1.05 percent. This is a 4.12 percent decrease over sales of $1.41 billion the same period last year.

Earnings Beats

AMC Enter Hldgs Q3 2024 Adj EPS $(0.04) Beats $(0.11) Estimate, Sales $1.35B Beat $1.33B Estimate

Barrett Bus Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBSI#NASDAQ">BBSI</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.69 by 7.25 percent. The company reported quarterly sales of $294.278 million which beat the analyst consensus estimate of $287.279 million by 2.44 percent. This is a 7.66 percent increase over sales of $273.328 million the same period last year.

Barrett Bus Servs Q3 2024 GAAP EPS $0.74 Beats $0.69 Estimate, Sales $294.278M Beat $287.279M Estimate

Reaffirming Fiscal Year 2025 Outlook
Kyndryl is reaffirming its outlook for its fiscal year 2025, which runs from April 2024 to March 2025:
<ul>
<li>Adjusted EBITDA margin of at least 16.3%, representing a year-over-year increase of at least 160 basis points.</li>
<li>Adjusted pretax income of at least $460 million, representing a year-over-year increase of at least $295 million.</li>
<li>Constant-currency revenue growth of (2%) to (4%), which now implies fiscal 2025 revenue of $15.2 to $15.5 billion based on recent exchange rates. The Company continues to expect to deliver year-over-year constant-currency revenue growth in the fourth quarter of the fiscal year.</li>
<li>Adjusted free cash flow of approximately $300 million.</li>
</ul>
Forecasted amounts are based on currency exchange rates as of October 2024.

Kyndryl Reaffirming FY25 Revenue Growth Outlook Of (2%) To (4%), Which Now Implies Fiscal 2025 Revenue Of $15.2B-$15.5B Vs $15.27B Est.

EnerSys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENS#NYSE">ENS</a>) reported quarterly earnings of $2.05 per share which missed the analyst consensus estimate of $2.07 by 0.97 percent. The company reported quarterly sales of $883.700 million which missed the analyst consensus estimate of $887.696 million by 0.45 percent. This is a 1.92 percent decrease over sales of $901.000 million the same period last year.

EnerSys Q2 2025 Adj. EPS $2.05 Misses $2.07 Estimate, Sales $883.700M Miss $887.696M Estimate

Coherent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.61 by 21.31 percent. This is a 362.5 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $1.35 billion which beat the analyst consensus estimate of $1.31 billion by 2.72 percent. This is a 28.02 percent increase over sales of $1.05 billion the same period last year.

COHR

Coherent Q1 2025 Adj EPS $0.74 Beats $0.61 Estimate, Sales $1.35B Beat $1.31B Estimate

Crane NXT Narrows FY24 Adj. EPS From $4.10-$4.35 To $4.22-$4.30 Vs $4.26 Est; Sees Sales Growth 6%-8%

Tanger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>) raises FY2024 FFO guidance from $2.05-2.12 to $2.09-2.13 vs $2.09 analyst estimate..

Tanger Raises FY2024 FFO Guidance from $2.05-2.12 to $2.09-2.13 vs $2.09 Est

Guardant Health Raises FY24 Revenue From $690M-$700M To $720M-$725M Vs $695.221M Est.

ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.77 by 41.56 percent. This is a 68.75 percent decrease over earnings of $1.44 per share from the same period last year. The company reported quarterly sales of $702.04 million which missed the analyst consensus estimate of $714.92 million by 1.80 percent. This is a 2.20 percent increase over sales of $686.92 million the same period last year.

MODV

ModivCare Q3 Adj $0.45 Misses $0.77 Estimate, Sales $702.04M Miss $714.92M Estimate

2024 Financial Guidance
The company now expects 2024 Adjusted EBITDA between $7 billion and $7.150 billion, which is an increase to the midpoint of guidance by $125 million. In addition, the company continues to expect 2024 growth capex between $1.45 billion and $1.75 billion and maintenance capex between $1.1 billion and $1.3 billion, which includes capital of $350 million for emissions reduction and modernization initiatives. For 2025, the company continues to expect Adjusted EBITDA between $7.2 billion and $7.6 billion with growth capex between $1.65 billion and $1.95 billion and maintenance capex between $750 million and $850 million, which includes capital of $100 million for emissions reduction and modernization initiatives. Williams anticipates a leverage ratio midpoint for 2024 of 3.80x and an increase in the dividend by 6.1% on an annualized basis to $1.90 in 2024 from $1.79 in 2023.

Williams Sees FY24 Adj. EBITDA $7B-$7.15B

Outlook
The company is providing the following guidance for fiscal 2025:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Fiscal 2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues</td>
<td colspan="1" rowspan="1">$1.98 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP Net Income</td>
<td colspan="1" rowspan="1">$624 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP EPS</td>
<td colspan="1" rowspan="1">$25.05</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP Net Income</td>
<td colspan="1" rowspan="1">$712 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP EPS</td>
<td colspan="1" rowspan="1">$28.58</td>
</tr>
</tbody>
</table>
</figure>
The Non-GAAP financial measures are described in the financial table captioned "Reconciliation of Non-GAAP Guidance."

FICO

Fair Isaac Corp Sees FY25 EPS $28.58 Vs $29.75 Est.; Revenue $1.98B Vs $1.98B Est.

<a href="https://www.youtube.com/live/WckEFzGku0Q?si=xYoX2IKIbpXW2PQ7" title="https://www.youtube.com/live/WckEFzGku0Q?si=xYoX2IKIbpXW2PQ7">https://www.youtube.com/live/WckEFzGku0Q?si=xYoX2IKIbpXW2PQ7</a>

General

LIVE: Kamala Harris delivers concession speech - AP

Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) is looking for Q4 Adj EPS of $0.48-0.51 vs $0.53 analyst estimate. seessales of $211.000 million-213.000 million vs $211.77 million estimate.

Rapid7 Sees Q4 Adj EPS $0.48-0.51 vs $0.53 Est; Sees Sales $211.000M-213.000M vs $211.77M Est

Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent. The company reported quarterly sales of $26.082 million which missed the analyst consensus estimate of $29.843 million by 12.60 percent. This is a 147.62 percent increase over sales of $10.533 million the same period last year.

RXRX

Recursion Pharmaceuticals Q3 2024 GAAP EPS $(0.34) Beats $(0.37) Estimate, Sales $26.082M Miss $29.843M Estimate

TTEC Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEC#NASDAQ">TTEC</a>) lowers FY2024 Adj EPS guidance from $0.74-0.97 to $0.64-0.83 vs $0.80 analyst estimate. Affirms FY2024 sales outlook from $2.21 billion-2.26 billion to $2.21 billion-2.26 billion vs $2.22 billion estimate.

TTEC

TTEC Holdings Lowers FY2024 Adj EPS Guidance from $0.74-0.97 to $0.64-0.83 vs $0.80 Est; Affirms FY2024 Sales Guidance from $2.21B-2.26B to $2.21B-2.26B vs $2.22B Est

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals INC successfully completed a public offering on July 15, 2024, rais...

Universe Pharmaceuticals Raises $25 Million in Offering

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals Inc announces its upcoming annual general meeting scheduled for Sep...

Universe Pharmaceuticals' Key Shareholder Meeting

Jones Research starts Larimar at buy, cites lead asset nomlabofusp

Universe Pharmaceuticals GAAP EPS of -$3.59, revenue of $12.88M

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals has reported a decrease in total assets from $53.3 million to $49.4...

Universe Pharmaceuticals Reports Financial Downturn

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals INC successfully conducted its 2024 Annual General Meeting, securin...

Universe Pharmaceuticals Secures Strong Shareholder Backing

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals has confirmed its agreement with the contents of Form 6-K filed on ...

Universe Pharmaceuticals Confirms Financial Filing Accuracy

Universe Pharmaceuticals receives non-compliance letter from Nasdaq

Universe Pharmaceuticals (UPC) announced that the Company received a written notification from the Nasdaq Stock Market LLC on October 25, 2024, not...

Universe Pharmaceuticals receives Nasdaq notification over bid price deficiency

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals has received a notification from Nasdaq regarding its non-complianc...

Comments

Universe Pharmaceuticals

Vendite allo scoperto

Universe Pharmaceuticals (NASDAQ:UPC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO